According to Zacks, “Aridis Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the discovery and development of immunotherapy using fully human monoclonal antibodies to treat life-threatening infections. The company’s product pipeline consists of AR-301, AR-105, AR-101, AR-401, AR-201 and AR-501 which are in clinical stages. Aridis Pharmaceuticals, Inc. is based in San Jose, United States. “
Other research analysts also recently issued research reports about the company. Maxim Group set a $25.00 price objective on Aridis Pharmaceuticals and gave the company a buy rating in a research note on Tuesday, September 3rd. Northland Securities reaffirmed a buy rating and issued a $40.00 price objective on shares of Aridis Pharmaceuticals in a research note on Tuesday, August 13th. ValuEngine raised Aridis Pharmaceuticals from a hold rating to a buy rating in a research note on Thursday, August 1st. Finally, Laidlaw set a $15.00 price objective on Aridis Pharmaceuticals and gave the company a buy rating in a research note on Wednesday, September 4th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. The company has an average rating of Buy and an average price target of $23.40.
Aridis Pharmaceuticals (NASDAQ:ARDS) last released its quarterly earnings data on Monday, August 12th. The company reported ($1.03) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.84) by ($0.19). Aridis Pharmaceuticals had a negative net margin of 660.52% and a negative return on equity of 130.22%. As a group, equities research analysts predict that Aridis Pharmaceuticals will post -3.78 EPS for the current fiscal year.
About Aridis Pharmaceuticals
Aridis Pharmaceuticals Inc, a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S.
Further Reading: How Does the Quiet Period Work?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aridis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aridis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.